NASDAQ:PRTA - Nasdaq - IE00B91XRN20 - Common Stock - Currency: USD
15.56
+0.31 (+2.03%)
The current stock price of PRTA is 15.56 USD. In the past month the price increased by 0.52%. In the past year, price decreased by -42.84%.
Symbol | Name | TA | FA | PE | Market Cap |
---|---|---|---|---|---|
ABBV | ABBVIE INC | 19.97 | 357.10B | ||
AMGN | AMGEN INC | 15.29 | 162.72B | ||
GILD | GILEAD SCIENCES INC | 23.85 | 137.00B | ||
VRTX | VERTEX PHARMACEUTICALS INC | 1669.79 | 124.40B | ||
REGN | REGENERON PHARMACEUTICALS | 15.34 | 76.56B | ||
ARGX | ARGENX SE - ADR | N/A | 39.16B | ||
ALNY | ALNYLAM PHARMACEUTICALS INC | N/A | 32.32B | ||
BNTX | BIONTECH SE-ADR | N/A | 28.77B | ||
ONC | BEIGENE LTD-ADR | N/A | 27.25B | ||
NTRA | NATERA INC | N/A | 21.43B | ||
BIIB | BIOGEN INC | 8.54 | 20.49B | ||
SMMT | SUMMIT THERAPEUTICS INC | N/A | 16.31B |
Prothena Corp. Plc is a clinical-stage neuroscience company, which engages in the discovery and development of novel therapies to change the course of devastating diseases. The firm is engaged in protein dysregulation and a pipeline of investigational therapeutics for rare peripheral amyloid diseases. The firm is advancing a pipeline of therapeutic candidates for a range of indications and targets to integrate scientific insights around neurological dysfunction and the biology of misfolded proteins. The Company’s pipeline includes both wholly owned and partnered programs being developed for the potential treatment of diseases, including AL amyloidosis, ATTR amyloidosis, Alzheimer’s disease, Parkinson’s disease and a range of other neurodegenerative diseases. Its clinical programs include birtamimab for the potential treatment of AL amyloidosis, prasinezumab for the potential treatment of Parkinson’s disease, NNC6019/PRX004 for the potential treatment of ATTR amyloidosis, and PRX005 and PRX012 for the potential treatment of Alzheimer’s disease.
PROTHENA CORP PLC
77 Sir John Rogersons Quay, Block C, Grand Canal Docklands
DUBLIN D02 VK60 IE
CEO: Gene G. Kinney
Employees: 173
Company Website: https://www.prothena.com/
Investor Relations: https://ir.prothena.com/
Phone: 35312362500
The current stock price of PRTA is 15.56 USD. The price increased by 2.03% in the last trading session.
The exchange symbol of PROTHENA CORP PLC is PRTA and it is listed on the Nasdaq exchange.
PRTA stock is listed on the Nasdaq exchange.
16 analysts have analysed PRTA and the average price target is 44.88 USD. This implies a price increase of 188.43% is expected in the next year compared to the current price of 15.56. Check the PROTHENA CORP PLC stock analysts ratings, price target forecast and up-and down grades for more detailed information.
PROTHENA CORP PLC (PRTA) has a market capitalization of 837.28M USD. This makes PRTA a Small Cap stock.
PROTHENA CORP PLC (PRTA) currently has 173 employees.
PROTHENA CORP PLC (PRTA) has a support level at 14.04 and a resistance level at 15.63. Check the full technical report for a detailed analysis of PRTA support and resistance levels.
The Revenue of PROTHENA CORP PLC (PRTA) is expected to grow by 56.55% in the next year. Check the estimates tab for more information on the PRTA EPS, Sales, EBIT and EBITDA future analyst estimates.
There is no straightforward answer here. It depends on your investment strategy as different types of investors will look at different aspects. In any case it is important to make an informed decision and these pages can help you forming an opinion:
PRTA does not pay a dividend.
PROTHENA CORP PLC (PRTA) will report earnings on 2025-05-06, after the market close.
PROTHENA CORP PLC (PRTA) does not have a PE ratio as the earnings reported over the last twelve months were negative (-2.48).
The outstanding short interest for PROTHENA CORP PLC (PRTA) is 19.11% of its float. Check the ownership tab for more information on the PRTA short interest.
ChartMill assigns a technical rating of 3 / 10 to PRTA. When comparing the yearly performance of all stocks, PRTA is a bad performer in the overall market: 84.01% of all stocks are doing better.
ChartMill assigns a fundamental rating of 4 / 10 to PRTA. No worries on liquidiy or solvency for PRTA as it has an excellent financial health rating, but there are worries on the profitability.
Over the last trailing twelve months PRTA reported a non-GAAP Earnings per Share(EPS) of -2.48. The EPS decreased by -74.65% compared to the year before.
Industry Rank | Sector Rank | ||
---|---|---|---|
PM (TTM) | N/A | ||
ROA | -22.15% | ||
ROE | -24.67% | ||
Debt/Equity | 0 |
ChartMill assigns a Buy % Consensus number of 81% to PRTA. The Buy consensus is the average rating of analysts ratings from 16 analysts.
For the next year, analysts expect an EPS growth of 18.51% and a revenue growth 56.55% for PRTA